U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information Guidance for Industry June 2016

Final
Docket Number:
FDA-2010-D-0500
Issued by:
Guidance Issuing Office
Center for Biologics Evaluation and Research

This guidance is intended to provide sponsors of Investigational New Drug Applications (INDs) with recommendations on submissions for early clinical trials with live biotherapeutic products (LBPs) in the United States (U.S.), including LBPs lawfully marketed as foods (such as conventional foods and dietary supplements) in the U.S. and proposed for clinical uses regulated under section 351 of the Public Health Service (PHS) Act (42 U.S.C. 262).

This guidance focuses on the chemistry, manufacturing, and control (CMC) information and is applicable to all INDs of LBPs, whether clinical trials are conducted commercially, in an academic setting, or otherwise under Title 21 of the Code of Federal Regulations Part 312 (21 CFR Part 312). This guidance is not applicable to LBPs intended as gene therapy vectors, to oncolytic bacteria, or to oncolytic viruses.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2010-D-0500.

Back to Top